Avior Wealth Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Avior Wealth Management LLC increased its holdings in Gilead Sciences by 57.2% during the 2nd quarter, bringing their total shares to 7,530, valued at $790,000.
• Gilead Sciences reported earnings of $2.01 per share for the last quarter, exceeding analysts' expectations and achieving a 1.4% increase in quarterly revenue year-over-year.
• The company recently declared a quarterly dividend of $0.79 per share, with a dividend yield of 2.8% and a dividend payout ratio of 62.95%.

Avior Wealth Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 57.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,530 shares of the biopharmaceutical company's stock after buying an additional 2,739 shares during the period. Avior Wealth Management LLC's holdings in Gilead Sciences were worth $790,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth about $25,000. Activest Wealth Management boosted its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the period. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth about $29,000. Colonial Trust Advisors boosted its stake in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 213 shares during the period. Finally, Core Alternative Capital boosted its stake in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Trading Up 0.5%

Shares of Gilead Sciences stock opened at $112.62 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $82.82 and a 12-month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market cap of $139.74 billion, a PE ratio of 22.43, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36. The company has a 50-day moving average of $114.50 and a two-hundred day moving average of $109.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same period last year, the company posted $2.01 earnings per share. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company's stock, valued at $978,880.80. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,000 shares of company stock valued at $8,285,530. Company insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GILD shares. UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research report on Tuesday, August 19th. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, September 16th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.